CHARLOTTE, N.C., June 6, 2006 (PRIMEZONE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Pacific Growth Equities Life Sciences Growth Conference at 2:00 PM PDT Tuesday, June 13th at the InterContinental Mark Hopkins hotel in San Francisco, CA.
Dr. Simon Pedder, President and CEO of Chelsea Therapeutics, will provide a corporate overview including an introduction to the company's recently announced Droxidopa development program and I-3D compounds under development in partnership with Active Biotech.
A live audio webcast of the presentation can be accessed on the investor relations page of the company's website, www.chelseatherapeutics.com. An audio replay of the presentation will also be available for 90 days after the conference.
About Chelsea Therapeutics
Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea develops technologies that address important unmet medical needs or offer improved, cost-effective alternatives to current methods of treatment. Early clinical data suggests that Chelsea's lead product candidate, CH-1504, may support a safe and effective treatment for rheumatoid arthritis and may have further applications for psoriasis, certain cancers and other immunological disorders.
This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include reliance on collaborations and licenses, risks and costs of drug development, regulatory approvals, intellectual property risks, our reliance on our lead drug candidate CH-1504, our history of losses and need to raise more money, competition, market acceptance for our products if any are approved for marketing, reliance on key personnel including specifically Dr. Pedder, management of rapid growth, and the need to acquire or develop additional products.